Abstract:The Cystine-xCT transporter-Glutathione (GSH)-GPX4 axis is the canonical pathway to protect against ferroptosis. While not required for ferroptosis-inducing compounds (FINs) targeting GPX4, FINs targeting the xCT transporter require mitochondria and its lipid peroxidation to trigger ferroptosis. However, the mechanism underlying the difference between these FINs is still unknown. Given that cysteine is also required for coenzyme A (CoA) biosynthesis, here we show that CoA supplementation specifically prevents ferroptosis induced by xCT inhibitors but not GPX4 inhibitors. We find that, auranofin, a thioredoxin reductase inhibitor, abolishes the protective effect of CoA. We also find that CoA availability determines the enzymatic activity of thioredoxin reductase, but not thioredoxin. Importantly, the mitochondrial thioredoxin system, but not the cytosolic thioredoxin system, determines CoA-mediated ferroptosis inhibition. Our data show that the CoA regulates the in vitro enzymatic activity of mitochondrial thioredoxin reductase (TXNRD2) by covalently modifying the thiol group of cysteine (CoAlation) on Cys-483. Replacing Cys-483 with alanine on TXNRD2 abolishes its in vitro enzymatic activity and ability to protect cells from ferroptosis. Targeting xCT to limit cysteine import and, therefore, CoA biosynthesis reduced CoAlation on TXNRD2, an effect that was rescued by CoA supplementation. Furthermore, the fibroblasts from patients with disrupted CoA metabolism demonstrate increased mitochondrial lipid peroxidation. In organotypic brain slice cultures, inhibition of CoA biosynthesis leads to an oxidized thioredoxin system, mitochondrial lipid peroxidation, and loss in cell viability, which were all rescued by ferrostatin-1. These findings identify CoA-mediated post-translation modification to regulate the thioredoxin system as an alternative ferroptosis protection pathway with potential clinical relevance for patients with disrupted CoA metabolism.

Non-canonical glutamate-cysteine ligase activity protects against ferroptosis

Mitochondrial respiratory function is preserved under cysteine starvation via glutathione catabolism in NSCLC

LKB1-AMPK Axis Negatively Regulates Ferroptosis by Inhibiting Fatty Acid Synthesis

The enzyme glutamate-cysteine ligase (GCL) is a target for ferroptosis induction in cancer

Coenzyme A protects against ferroptosis via CoAlation of thioredoxin reductase 2

Unresolved questions regarding cellular cysteine sources and their possible relationships to ferroptosis

Cysteine and homocysteine can be exploited by GPX4 in ferroptosis inhibition independent of GSH synthesis

Cystine/Glutamate Exchange Modulates Glutathione Supply for Neuroprotection from Oxidative Stress and Cell Proliferation

Ferroptosis inhibition by lysosome-dependent catabolism of extracellular protein

Protein CoAlation on TXNRD2 regulates mitochondrial thioredoxin system to protect against ferroptosis

γ-Glutamylcysteine Exerts Neuroprotection Effects against Cerebral Ischemia/Reperfusion Injury through Inhibiting Lipid Peroxidation and Ferroptosis

Protein S-glutathionylation confers cell resistance to ferroptosis

Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8 + T cells

Glutaminolysis and Transferrin Regulate Ferroptosis

The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death

The CRL3KCTD10 ubiquitin ligase–USP18 axis coordinately regulates cystine uptake and ferroptosis by modulating SLC7A11

Golgi stress mediates redox imbalance and ferroptosis in human cells

NFE2L2 and SLC25A39 drive cuproptosis resistance through GSH metabolism

Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism

Cystine Induced-mTORC2 Activation through Promoting Sin1 Phosphorylation to Suppress Cancer Cell Ferroptosis

Structural and functional fine mapping of cysteines in mammalian glutaredoxin reveal their differential oxidation susceptibility